These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 11993366

  • 21. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS, Angell M.
    New Repub; 2002 Dec 16; 227(25):27-41. PubMed ID: 12561803
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Trouble at the office.
    Allison M.
    Nat Biotechnol; 2008 Sep 16; 26(9):967-9. PubMed ID: 18779797
    [No Abstract] [Full Text] [Related]

  • 24. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R.
    J Natl Cancer Inst; 2005 May 18; 97(10):708-9. PubMed ID: 15900036
    [No Abstract] [Full Text] [Related]

  • 25. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ.
    Food Drug Law J; 2007 May 18; 62(1):77-137. PubMed ID: 17444027
    [No Abstract] [Full Text] [Related]

  • 26. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S, Strom BL.
    N Engl J Med; 2007 Apr 26; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract] [Full Text] [Related]

  • 27. From laboratory to medicine cabinet.
    Caring; 1992 Nov 26; 11(11):16-20. PubMed ID: 10121248
    [Abstract] [Full Text] [Related]

  • 28. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 Nov 26; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 29. Muddied messages about FDA.
    Miller HI.
    Nat Biotechnol; 2003 Jul 26; 21(7):732-3. PubMed ID: 12833084
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2009 Jul 26; 22(1):30-8. PubMed ID: 19209297
    [Abstract] [Full Text] [Related]

  • 32. Will politics sidetrack FDA reform?
    Gatty B.
    Formulary; 1995 Aug 26; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract] [Full Text] [Related]

  • 33. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J, Smith B, Courtney B, Mair M.
    Clin Pharmacol Ther; 2009 Jun 26; 85(6):571-2. PubMed ID: 19451907
    [No Abstract] [Full Text] [Related]

  • 34. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW, Rappaport BA.
    Anesth Analg; 2007 Mar 26; 104(3):479-80. PubMed ID: 17312189
    [No Abstract] [Full Text] [Related]

  • 35. Perspectives. GOP sets its sights on Food and Drug Administration.
    Barnett AA.
    Faulkner Grays Med Health; 1995 Feb 20; 49(8):suppl 1-4. PubMed ID: 10139918
    [No Abstract] [Full Text] [Related]

  • 36. New drug law to speed scientific review.
    Nature; 1992 Oct 15; 359(6396):563. PubMed ID: 1406977
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Piercing the veil of corporate secrecy about clinical trials.
    Lemmens T.
    Hastings Cent Rep; 2004 Oct 15; 34(5):14-8. PubMed ID: 15553393
    [No Abstract] [Full Text] [Related]

  • 39. Companies throw their weight behind new antiobesity drugs.
    Cahoon L.
    Nat Med; 2010 Feb 15; 16(2):136. PubMed ID: 20134442
    [No Abstract] [Full Text] [Related]

  • 40. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA.
    Food Drug Law J; 2003 Feb 15; 58(1):103-27. PubMed ID: 12739592
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.